دورية أكاديمية
أعرض في EDS

Resveratrol and Curcumin for Chagas Disease Treatment-A Systematic Review.

التفاصيل البيبلوغرافية
العنوان: Resveratrol and Curcumin for Chagas Disease Treatment-A Systematic Review.
المؤلفون: Imperador CHL; Advanced Research Center in Medicine (CEPAM), School of Medicine, Union of the Colleges of the Great Lakes (UNILAGO), Sao Jose do Rio Preto 15030-070, SP, Brazil., Scarim CB; Laboratory of Drug Design (LAPDESF), School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Araraquara 14800-903, SP, Brazil., Bosquesi PL; Advanced Research Center in Medicine (CEPAM), School of Medicine, Union of the Colleges of the Great Lakes (UNILAGO), Sao Jose do Rio Preto 15030-070, SP, Brazil.; Laboratory of Drug Design (LAPDESF), School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Araraquara 14800-903, SP, Brazil., Lopes JR; Laboratory of Drug Design (LAPDESF), School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Araraquara 14800-903, SP, Brazil.; Chemical Institute, University of São Paulo State (UNESP), Araraquara 14800-900, SP, Brazil., Cardinalli Neto A; Advanced Research Center in Medicine (CEPAM), School of Medicine, Union of the Colleges of the Great Lakes (UNILAGO), Sao Jose do Rio Preto 15030-070, SP, Brazil.; Faculdade de Medicina de São José do Rio Preto ( FAMERP), Sao Jose do Rio Preto 15090-000, SP, Brazil., Giarolla J; Laboratory of Synthesis and Drug Design for Neglected Disease (LAPEN), School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo 05508-220, SP, Brazil., Ferreira EI; Laboratory of Synthesis and Drug Design for Neglected Disease (LAPEN), School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo 05508-220, SP, Brazil., Dos Santos JL; Laboratory of Drug Design (LAPDESF), School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Araraquara 14800-903, SP, Brazil.; Chemical Institute, University of São Paulo State (UNESP), Araraquara 14800-900, SP, Brazil., Chin CM; Advanced Research Center in Medicine (CEPAM), School of Medicine, Union of the Colleges of the Great Lakes (UNILAGO), Sao Jose do Rio Preto 15030-070, SP, Brazil.; Laboratory of Drug Design (LAPDESF), School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Araraquara 14800-903, SP, Brazil.
المصدر: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2022 May 15; Vol. 15 (5). Date of Electronic Publication: 2022 May 15.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c2004-
مستخلص: Chagas disease (CD) is a neglected protozoan infection caused by Trypanosoma cruzi , which affects about 7 million people worldwide. There are two available drugs in therapeutics, however, they lack effectiveness for the chronic stage-characterized mainly by cardiac (i.e., cardiomyopathy) and digestive manifestations (i.e., megaesophagus, megacolon). Due to the involvement of the immuno-inflammatory pathways in the disease's progress, compounds exhibiting antioxidant and anti-inflammatory activity seem to be effective for controlling some clinical manifestations, mainly in the chronic phase. Resveratrol (RVT) and curcumin (CUR) are natural compounds with potent antioxidant and anti-inflammatory properties and their cardioprotective effect have been proposed to have benefits to treat CD. Such effects could decrease or block the progression of the disease's severity. The purpose of this systematic review is to analyze the effectiveness of RVT and CUR in animal and clinical research for the treatment of CD. The study was performed according to PRISMA guidelines and it was registered on PROSPERO (CDR42021293495). The results did not find any clinical study, and the animal research was analyzed according to the SYRCLES risk of bias tools and ARRIVE 2.0 guidelines. We found 9 eligible reports in this study. We also discuss the potential RVT and CUR derivatives for the treatment of CD as well.
References: Biofactors. 2018 Jan;44(1):69-82. (PMID: 29210129)
Adv Food Nutr Res. 2010;59:63-85. (PMID: 20610174)
Med Clin (Barc). 2017 Feb 9;148(3):125-131. (PMID: 27993415)
PLoS Negl Trop Dis. 2011 Feb 01;5(2):e953. (PMID: 21408103)
Biomed Rep. 2015 Nov;3(6):743-748. (PMID: 26623010)
Future Med Chem. 2021 Apr;13(8):701-714. (PMID: 33648346)
Lancet. 2018 Jan 6;391(10115):82-94. (PMID: 28673423)
Adv Parasitol. 2011;76:171-94. (PMID: 21884892)
Antimicrob Agents Chemother. 2017 Feb 23;61(3):. (PMID: 27993857)
Ageing Res Rev. 2021 May;67:101271. (PMID: 33571701)
Mem Inst Oswaldo Cruz. 2022 Mar 30;117:e220396. (PMID: 35352776)
BMB Rep. 2019 Jan;52(1):24-34. (PMID: 30526767)
Int J Mol Sci. 2021 Sep 21;22(18):. (PMID: 34576315)
Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7500-7508. (PMID: 30468499)
Crit Rev Food Sci Nutr. 2018 Jun 13;58(9):1428-1447. (PMID: 28001084)
Dev Biol. 2016 Sep 15;417(2):217-28. (PMID: 27059882)
Annu Rev Pathol. 2019 Jan 24;14:421-447. (PMID: 30355152)
N Engl J Med. 2015 Jul 30;373(5):456-66. (PMID: 26222561)
Crit Rev Food Sci Nutr. 2019;59(6):882-892. (PMID: 29999408)
Phytother Res. 2014 Nov;28(11):1581-8. (PMID: 24919577)
Mem Inst Oswaldo Cruz. 2018 Jul 16;113(9):e180171. (PMID: 30020318)
Cell Physiol Biochem. 2018;46(4):1381-1397. (PMID: 29689567)
Clin Infect Dis. 2012 Mar;54(6):845-52. (PMID: 22238161)
Antimicrob Agents Chemother. 2016 May 23;60(6):3355-64. (PMID: 27001816)
Rev Soc Bras Med Trop. 2020 Oct 21;53:e20200225. (PMID: 33111908)
J Cardiovasc Pharmacol. 2014 Jun;63(6):567-76. (PMID: 24492474)
Front Immunol. 2021 Nov 11;12:755862. (PMID: 34867992)
Int J Mol Sci. 2019 Feb 19;20(4):. (PMID: 30791450)
Rev Soc Bras Med Trop. 2013 Sep-Oct;46(5):536-41. (PMID: 23904079)
Br J Pharmacol. 2009 Jun;157(3):381-91. (PMID: 19371352)
Med Res Rev. 2019 Sep;39(5):1851-1891. (PMID: 30741437)
Free Radic Biol Med. 2004 Mar 15;36(6):774-81. (PMID: 14990356)
Oxid Med Cell Longev. 2018 Oct 30;2018:8152373. (PMID: 30510627)
Front Pharmacol. 2021 Apr 22;12:644219. (PMID: 33967780)
Pharmacol Ther. 2020 Oct;214:107613. (PMID: 32562826)
Drugs Today (Barc). 2021 Apr;57(4):251-263. (PMID: 33851689)
Dysphagia. 2021 Jun;36(3):517-522. (PMID: 33855597)
PLoS One. 2016 Sep 22;11(9):e0162926. (PMID: 27658305)
J Biol Chem. 2004 Dec 3;279(49):51163-71. (PMID: 15383533)
SAGE Open Med. 2019 Dec 18;7:2050312119895927. (PMID: 31897298)
Endosc Int Open. 2020 Apr;8(4):E506-E512. (PMID: 32258372)
Mol Pharm. 2007 Nov-Dec;4(6):807-18. (PMID: 17999464)
Infect Dis Clin North Am. 2019 Mar;33(1):119-134. (PMID: 30712757)
Int J Biol Macromol. 2016 Jun;87:498-503. (PMID: 26976067)
Molecules. 2019 Aug 13;24(16):. (PMID: 31412624)
Front Pharmacol. 2018 Feb 19;9:102. (PMID: 29515440)
Int J Mol Med. 2019 Jan;43(1):630-640. (PMID: 30387805)
Am J Trop Med Hyg. 2011 Feb;84(2):325-31. (PMID: 21292909)
Antioxidants (Basel). 2022 Jan 20;11(2):. (PMID: 35204079)
Parasitol Res. 2012 Jun;110(6):2491-9. (PMID: 22215192)
Molecules. 2021 Jan 05;26(1):. (PMID: 33466247)
Semin Diagn Pathol. 2019 May;36(3):164-169. (PMID: 31006555)
Nature. 2006 Nov 16;444(7117):337-42. (PMID: 17086191)
J Nucl Cardiol. 2020 Apr;27(2):445-451. (PMID: 30022404)
Eur J Pharmacol. 2003 Mar 28;465(1-2):115-23. (PMID: 12650840)
Mol Neurobiol. 2018 Mar;55(3):2085-2101. (PMID: 28283884)
Pharmacol Res. 2021 Jan;163:105287. (PMID: 33157235)
Mol Med Rep. 2019 Sep;20(3):2783-2795. (PMID: 31524255)
PLoS Pathog. 2016 Oct 27;12(10):e1005947. (PMID: 27788262)
Ann N Y Acad Sci. 2017 Sep;1403(1):142-149. (PMID: 28815614)
Mediators Inflamm. 2014;2014:475946. (PMID: 25221388)
Front Cell Infect Microbiol. 2021 Nov 12;11:765879. (PMID: 34869068)
Br J Pharmacol. 2017 Jun;174(12):1633-1646. (PMID: 27058985)
Nutrients. 2019 Jan 11;11(1):. (PMID: 30641865)
Antioxidants (Basel). 2021 Mar 03;10(3):. (PMID: 33802566)
Molecules. 2014 Oct 09;19(10):16102-21. (PMID: 25302702)
Microb Pathog. 2019 Jul;132:156-161. (PMID: 31029718)
Phytomedicine. 2016 Nov 15;23(12):1392-1400. (PMID: 27765359)
Molecules. 2016 Feb 25;21(3):264. (PMID: 26927041)
J Med Food. 2011 Oct;14(10):1173-80. (PMID: 21554123)
PLoS Pathog. 2016 Oct 20;12(10):e1005954. (PMID: 27764247)
Parasitol Int. 2021 Apr;81:102248. (PMID: 33238215)
Curr Pharm Des. 2018;24(2):123-129. (PMID: 29141538)
Mem Inst Oswaldo Cruz. 2012 Jun;107(4):513-21. (PMID: 22666863)
Phytomedicine. 2020 Oct;77:153230. (PMID: 32682225)
Biomed Pharmacother. 2020 May;125:109767. (PMID: 32058210)
BMC Med Res Methodol. 2014 Mar 26;14:43. (PMID: 24667063)
Ann N Y Acad Sci. 2011 Jan;1215:9-15. (PMID: 21261636)
Am J Med. 2020 Nov;133(11):1262-1265. (PMID: 32592664)
Molecules. 2019 Dec 09;24(24):. (PMID: 31835371)
Nutrients. 2018 Nov 03;10(11):. (PMID: 30400297)
Molecules. 2019 Mar 21;24(6):. (PMID: 30901941)
Int J Mol Sci. 2019 Mar 19;20(6):. (PMID: 30893846)
Int J Mol Sci. 2021 Jul 31;22(15):. (PMID: 34361023)
Biotechnol Adv. 2020 Jan - Feb;38:107343. (PMID: 30716389)
Cell Metab. 2012 May 2;15(5):675-90. (PMID: 22560220)
PLoS Biol. 2020 Jul 14;18(7):e3000411. (PMID: 32663221)
Biomed Pharmacother. 2019 Jan;109:886-891. (PMID: 30551542)
Viruses. 2020 Dec 17;12(12):. (PMID: 33348714)
Parasite Immunol. 2014 Aug;36(8):377-87. (PMID: 24611805)
Int J Surg. 2021 Apr;88:105906. (PMID: 33789826)
Antimicrob Agents Chemother. 2020 Jul 22;64(8):. (PMID: 32393497)
Eur J Pharmacol. 2016 Apr 5;776:26-33. (PMID: 26921129)
Mol Carcinog. 2020 Feb;59(2):227-236. (PMID: 31820492)
PLoS One. 2013 Aug 30;8(8):e73097. (PMID: 24023672)
Int J Antimicrob Agents. 2019 Jun;53(6):716-723. (PMID: 30825504)
Acta Biochim Biophys Sin (Shanghai). 2021 May 21;53(6):775-783. (PMID: 33891090)
Front Pharmacol. 2021 Jan 12;11:585821. (PMID: 33597872)
Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:226-35. (PMID: 19753478)
Mol Nutr Food Res. 2021 Nov;65(21):e2100434. (PMID: 34506670)
Acta Biochim Pol. 2019 Feb 28;66(1):13-21. (PMID: 30816367)
Microb Pathog. 2021 Apr;153:104800. (PMID: 33609651)
Chem Biol Interact. 2019 Jun 1;306:29-38. (PMID: 30954463)
Curr Med Chem. 2021;28(39):8036-8067. (PMID: 33881968)
Cardiovasc Drugs Ther. 2018 Apr;32(2):147-163. (PMID: 29556862)
Toxins (Basel). 2019 Dec 13;11(12):. (PMID: 31847250)
Nutrients. 2016 Nov 10;8(11):. (PMID: 27834913)
Nutrients. 2018 Dec 01;10(12):. (PMID: 30513737)
Rev Port Cardiol (Engl Ed). 2020 May;39(5):279-289. (PMID: 32532535)
فهرسة مساهمة: Keywords: Chagas disease; Trypanosoma cruzi; anti-inflammatory; curcumin; resveratrol
تواريخ الأحداث: Date Created: 20220528 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9143057
DOI: 10.3390/ph15050609
PMID: 35631435
قاعدة البيانات: MEDLINE
الوصف
تدمد:1424-8247
DOI:10.3390/ph15050609